Chemotherapy for advanced lung cancer

European Journal of Cancer

Volumn 40, Issue 16, 2004, Pages 2345-2348

  Blackhall, F ^a   Thatcher, N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM; TAXANE DERIVATIVE;

ALOPECIA; ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; EDITORIAL; FEBRILE NEUTROPENIA; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; SIDE EFFECT; SURVIVAL RATE; TOXICITY; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PLATINUM COMPOUNDS;

EID: 7044252847     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.06.026     Document Type: Editorial

References (21)

1. P.A. Bunn Chemotherapy for advanced non-small cell lung cancer: who, what, when, why? JCO 20 2002 23s 33s
2. F.A. Shepherd, F.V. Fossella, T. Lynch, J.P. Armand, J.R. Rigas, and M.G. Kris Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials Semin Oncol. 28 1 Suppl 2 2001 4 9
3. N. Hanna, F.A. Shepherd, F.V. Fossella, J.R. Pereira, F. De Marinis, and J. von Pawel Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy J. Clin. Oncol. 22 9 2004 1589 1597
4. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, et al. NCIC CTG, Kingston, ON, Canada A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proceedings of ASCO 2004, Abstract 7022
5. R. Booton, and N. Thatcher Chemotherapy in advanced non-small cell lung cancer: indication, intensity, and duration Curr. Opin. Oncol. 14 2002 191 198
6. C.J. Sweeney, J. Zhu, A.B. Sandler, J. Schiller, C.P. Belani, and C. Langer Outcome of patients with a performance status of 2 in Eastern Cooperative Group Study E1594, A Phase III trial in patients with metastatic non-small cell lung carcinoma Cancer 92 10 2001 2639 2647
7. Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, et al
8. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N. Engl. J. Med. 346 2 2002 92 98
9. K. Kelly, J. Crowley, and P.A. Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial J. Clin. Oncol. 19 13 2001 3210 3218
10. F. Fossella, J.R. Pereira, and J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small cell lung cancer: the TAX 326 study group J. Clin. Oncol. 21 16 2003 3016 3024 Epub 2003 Jul 01
11. T. Le Chevalier, and A. Brown Gemcitabine in the treatment of non-small cell lung cancer (NSCLC): A meta-analysis of survival and progression free survival data Lung Cancer 41 Suppl 2 2003 70 Abstract O-239
12. R. Rosell, U. Gatzemeier, and D.C. Betticher Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small cell lung cancer: a cooperative multinational trial Ann. Oncol. 13 10 2002 1539 1549
13. Zojwalla NJ, Raftopoulos H, Gralla RJ. Are cisplatin and carboplatin equivalent in the treatment of non-small cell lung carcinoma (NSCLC)? Results of a comprehensive review of randomized studies in over 2300 patients. Proceedings of ASCO 2004, Abstract 7068
14. P. Kosmidis, N. Mylonakis, and C. Nicolaides Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial J. Clin. Oncol. 20 17 2002 3578 3585
15. G. D'Addario, M. Pintilie, and T. Cerny Platinum-based versus non-platinum based chemotherapy in advanced non-small cell lung cancer (NSCLC): a meta-analysis of the published literature Lung Cancer 41 Suppl 2 2003 S68
16. E.F. Smit, J.P. van Meerbeeck, and P. Lianes Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975 J. Clin. Oncol. 21 21 2003 3909 3917
17. V. Georgoulias, E. Papadakis, and A. Alexopoulos Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial Lancet 357 9267 2001 1478 1484
18. Yamamoto N, Fukuoka M, Negoro S-I, Nakagawa K, Saito H, Matsui K, et al. for the West Japan Thoracic Oncology Group. BJC 2004, 90, 87-92
19. C. Gridelli, C. Gallo, and F.A. Shepherd Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 21 16 2003 3025 3034
20. R. Rosell, M. Taron, and A. Ariza Molecular predictors of response to chemotherapy in lung cancer Semin. Oncol. 31 1 Suppl 1 2004 20 27
21. T.J. Lynch, D.W. Bell, and R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib N. Engl. J. Med. 350 21 2004 2129 2139